



2021 FDA Novel Small Molecule Drug Approvals

Neurology (5)




samidorphan + olanzapine (Lybalvi)

opioid antagonist
schizophrenia, bipolar I disorder
oral: up to 10 + 20 mg QD*




viloxazine (Qelbree)

selective norepinephrine reuptake
inhibitor
ADHD
oral: up to 400 mg QD




atogepant (Qulipta)

calcitonin gene-related peptide (CGRP)
receptor antagonist
migraine
oral: up to 60 mg QD



ponesimod (Ponvory)

sphingosine 1-phosphate (S1P) receptor
modulator
multiple sclerosis
oral: up to 20 mg QD



serdexmethylphenidate + dexmethylphenidate (Azstarys)

catecholamine reuptake inhibitor, CNS
stimulant
ADHD
oral: up to 52.3 + 10.4 mg QD*